Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Collaboration symbols : Nrxp save search
NRx Pharmaceuticals, Lotus Pharmaceuticals and Alvogen Inc. Announce Collaboration to Develop and Commercialize NRX-101
Published: 2023-06-05 (Crawled : 11:00) - globenewswire.com
NRXP 1 d | $3.02 -27.75% -38.18% 4.6K
|
Manufacturing
|
| O: -0.85%
H: 8.1%
C: -26.08%
nrx-101 pharmaceuticals collaboration
Relief Reports that its U.S. Collaboration Partner has Announced that the FDA has Declined Emergency Use Authorization for Aviptadil for a Subgroup of Patients with Critical COVID-19 at Immediate Risk
Published: 2022-07-04 (Crawled : 10:00) - biospace.com/
RLFTF | $1.43 2.14% 11.45% 0
|
n/a
| Email alert
Add to watchlist
RLFTY | $1.4006 733.33% 100
|
n/a
| Email alert
Add to watchlist
NRXP 1 d | $3.02 -27.75% -38.18% 4.6K
|
Manufacturing
| Email alert
Add to watchlist
covid-19 fda risk collaboration aviptadil authorization emergency use authorization
Relief Reports that its U.S. Collaboration Partner has Announced an Update on Breakthrough Designation for Aviptadil
Published: 2022-06-13 (Crawled : 07:00) - biospace.com/
RLFTF | $1.43 2.14% 11.45% 0
|
n/a
|
| O: -10.92%
H: 14.19%
C: -0.32%
NRXP 1 d | $3.02 -27.75% -38.18% 4.6K
|
Manufacturing
|
| O: -8.21%
H: 7.26%
C: -3.08%
designation collaboration aviptadil
Relief Reports that its U.S. Collaboration Partner Announces Data Safety Monitoring Board (DSMB) Update on the U.S. National Institutes of Health (NIH) Study of aviptadil in Critical COVID-19
Published: 2022-05-26 (Crawled : 12:00) - biospace.com/
RLFTF | $1.43 2.14% 11.45% 0
|
n/a
|
| O: -9.48%
H: 4.19%
C: -39.05%
RLFTY | $1.4006 733.33% 100
|
n/a
|
| O: -40.54%
H: 20.91%
C: -15.45%
NRXP 1 d | $3.02 -27.75% -38.18% 4.6K
|
Manufacturing
|
| O: -38.37%
H: 1.11%
C: -32.16%
covid-19 collaboration aviptadil health
Relief Reports that its U.S. Collaboration Partner has Filed a New Breakthrough Therapy Designation Request for Aviptadil
Published: 2022-04-22 (Crawled : 09:00) - biospace.com/
RLFTF | $1.43 2.14% 11.45% 0
|
n/a
|
| O: -2.1%
H: 3.39%
C: -0.89%
NRXP 1 d | $3.02 -27.75% -38.18% 4.6K
|
Manufacturing
|
| O: -15.09%
H: 1.67%
C: -5.56%
designation collaboration aviptadil therapy
Relief Reports that its U.S. Collaboration Partner has Announced that the I-SPY COVID Trial Suggests No Clinical Benefit with Addition of Nebulized Aviptadil in Critically Ill Patients with COVID-19
Published: 2022-04-01 (Crawled : 08:00) - biospace.com/
RLFTF | $1.43 2.14% 11.45% 0
|
n/a
|
| O: -9.87%
H: 10.63%
C: 10.63%
NRXP 1 d | $3.02 -27.75% -38.18% 4.6K
|
Manufacturing
|
| O: 0.82%
H: 0.77%
C: -2.02%
covid-19 covid collaboration aviptadil trial
NRx Pharmaceuticals Files Counterclaim Against its Former Collaboration Partner, Relief Therapeutics
Published: 2022-01-12 (Crawled : 23:00) - prnewswire.com
NRXP 1 d | $3.02 -27.75% -38.18% 4.6K
|
Manufacturing
|
| O: -1.05%
H: 1.91%
C: -6.6%
als therapeutics collaboration
Relief Reports that its U.S. Collaboration Partner has Announced the Filing of a Provisional Patent Application for Stable Compositions of Aviptadil Suitable for Human Use
Published: 2022-01-04 (Crawled : 10:00) - biospace.com/
RLFTF | $1.43 2.14% 11.45% 0
|
n/a
|
| O: 8.45%
H: 6.1%
C: 6.1%
RLFTY | $1.4006 733.33% 100
|
n/a
|
| O: 10.09%
H: 0.0%
C: 0.0%
NRXP 1 d | $3.02 -27.75% -38.18% 4.6K
|
Manufacturing
|
| O: 6.8%
H: 0.0%
C: 0.0%
aviptadil application patent collaboration
Relief Reports that U.S. Collaboration Partner Announces New, Favorable Safety Report for Aviptadil in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19
Published: 2021-12-15 (Crawled : 09:00) - biospace.com/
NRXP 1 d | $3.02 -27.75% -38.18% 4.6K
|
Manufacturing
|
| O: -0.53%
H: 1.78%
C: -3.2%
covid-19 aviptadil covid collaboration pons
Relief Reports that its U.S. Collaboration Partner has Announced the U.S. Food and Drug Administration has Denied Breakthrough Designation for Aviptadil
Published: 2021-11-24 (Crawled : 08:00) - biospace.com/
NRXP 1 d | $3.02 -27.75% -38.18% 4.6K
|
Manufacturing
|
| O: -2.3%
H: 9.67%
C: 6.13%
food aviptadil collaboration drug designation
Relief Reports that its U.S. Collaboration Partner has Announced it has Received a U.S. Food and Drug Administration Review of Aviptadil Manufacturing Information
Published: 2021-11-12 (Crawled : 10:00) - biospace.com/
NRXP 1 d | $3.02 -27.75% -38.18% 4.6K
|
Manufacturing
|
| O: 5.6%
H: 0.0%
C: 0.0%
food aviptadil collaboration drug
Relief Reports U.S. Collaboration Partner's Emergency Use Authorization Request for ZYESAMI/RLF-100 (aviptadil) for Patients with Critical COVID-19 with Respiratory Failure was Declined by U.S. FDA
Published: 2021-11-05 (Crawled : 10:00) - biospace.com/
NRXP 1 d | $3.02 -27.75% -38.18% 4.6K
|
Manufacturing
|
| O: -39.12%
H: 30.27%
C: 17.7%
covid fda aviptadil zyesami collaboration respiratory merge emergency use authorization
Relief Reports U.S. Collaboration Partner has Announced Favorable New Safety Report for Aviptadil in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19
Published: 2021-11-03 (Crawled : 11:00) - biospace.com/
NRXP 1 d | $3.02 -27.75% -38.18% 4.6K
|
Manufacturing
|
| O: -1.24%
H: 2.94%
C: -1.57%
covid aviptadil collaboration
Relief Reports U.S. Collaboration Partner Announces Journal of Infectious Diseases and Treatment Publishes Positive Aviptadil Data in High Comorbidity Critical COVID-19 Patients w/ Respiratory Failure
Published: 2021-10-15 (Crawled : 09:00) - biospace.com/
NRXP 1 d | $3.02 -27.75% -38.18% 4.6K
|
Manufacturing
|
| O: -6.63%
H: 2.97%
C: -7.73%
covid disease treatment aviptadil infectious disease positive collaboration respiratory
Relief Reports that its U.S. Collaboration Partner has Announced Progress on Worldwide Commercial Scale Development of ZYESAMI(TM) (aviptadil)
Published: 2021-10-13 (Crawled : 09:00) - biospace.com/
NRXP 1 d | $3.02 -27.75% -38.18% 4.6K
|
Manufacturing
|
| O: 43.85%
H: 2.99%
C: -2.78%
collaboration aviptadil commercialization
Relief Reports that U.S. Collaboration Partner Announced Second Favorable Safety Report for ZYESAMI(TM) (RLF-100TM/aviptadil) in NIH Sponsored ACTIV-3b Critical Care Study in Life-Threatening COVID-19
Published: 2021-09-30 (Crawled : 09:00) - biospace.com/
NRXP 1 d | $3.02 -27.75% -38.18% 4.6K
|
Manufacturing
|
| O: 0.21%
H: 0.0%
C: -1.07%
covid collaboration aviptadil
Relief Reports that its U.S. Collaboration Partner has Announced Improved Survival at One Year in Highly Comorbid COVID-19 Patients Treated with ZYESAMITM (RLF-100TM/aviptadil)
Published: 2021-09-28 (Crawled : 08:00) - biospace.com/
NRXP 1 d | $3.02 -27.75% -38.18% 4.6K
|
Manufacturing
|
| O: -1.49%
H: 0.81%
C: -4.24%
covid collaboration aviptadil
IQVIA and NRx Pharmaceuticals Collaborate on Potential Medical Support for Novel COVID-19 Treatment
Published: 2021-09-13 (Crawled : 23:00) - biospace.com/
NRXP 1 d | $3.02 -27.75% -38.18% 4.6K
|
Manufacturing
|
| O: 0.0%
H: 0.25%
C: -8.88%
IQV | $227.17 -0.03% -0.2% 130
|
Health Services
|
| O: 0.63%
H: 0.15%
C: -2.51%
covid treatment potential collaboration covid-19
Relief Reports that U.S. Collaboration Partner has Announced a New Finding from Aviptadil Phase 2b/3 Trial Demonstrating Clinically Significant Relief from Respiratory Distress in Critical COVID-19
Published: 2021-08-31 (Crawled : 07:00) - biospace.com/
NRXP 1 d | $3.02 -27.75% -38.18% 4.6K
|
Manufacturing
|
| O: -1.11%
H: 8.62%
C: 8.07%
covid phase 2 collaboration respiratory phase 2b trial aviptadil
Relief Reports that its U.S. Collaboration Partner has Announced a Positive Safety Report for ZYESAMI(TM) (aviptadil) in NIH Sponsored ACTIV-3 Study in Patients with Life-Threatening COVID-19
Published: 2021-08-19 (Crawled : 07:00) - biospace.com/
NRXP 1 d | $3.02 -27.75% -38.18% 4.6K
|
Manufacturing
|
| O: -21.09%
H: 9.27%
C: 7.45%
covid positive collaboration aviptadil
Gainers vs Losers
| 53% | 47% |
Top 10 Gainers
HUBC | $1.52 17.83% 4.7M
|
n/a
NVCT | $6.88 2.38% 2.8K
|
ED | News | $91.43 0.58% 75K
|
Utilities
CWST | $92.75 0.41% 13K
|
Industrial Services
BCS | $9.27 0.33% 140K
|
Finance
RVMD S | $35.86 0.08% 36K
|
Health Technology
BIIB | $190.59 0.04% 50K
|
Health Technology
CMG | $2898.49 -0.33% 290
|
Consumer Services
CGAU | News | $6.04 -0.49% 2.8K
|
Mining, Quarrying, and Oil and ...
BELFB | $55.57 -0.82% 2K
|
Electronic Technology
Your saved searches
Save your searches and get alerts when important news are released.